NorthWest Biotherapeutics Inc (NWBO)

[CherryTree1]

That would be true that if we were tying to show that median survival was just slightly better with DCVAX say 2 months better like they did with the current SOC then completely agree not having a placebo control group randomly chosen from the full set of patients enrolled to the same criteria is problematic.

But that is not what we have here. There is such a eyepopping significant survival different between SOC and DCVAX it is no problem what so ever even if you discount a large number of the SOC historical population. you will still have a 2X - 3X overall survival improvement not 2 months but years of difference.

Again from the still blinded data on all 331 patients
https://nwbio.com/updated-interim-data-from-phase-3-trial-of-dcvax-l-for-glioblastoma/
Survival at 3 years is 28.2%
Survival at 3 years for 41.1% (methylated)

The historical GBM SOC survival
https://www.nature.com/articles/s41598-020-68011-4#:~:text=%25%2C%20respectively36.-,Discussion,glioblastoma%20during%20or%20after%202005.
3-year survival was 11%,
and 5-year survival was 4%
The recent historical SOC GBM survival curves from many different sources are all pretty much dead on.